Beta-blockers, renin-angiotensin system inhibitors, and cardiovascular outcomes during trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials
Background Trastuzumab has substantially improved clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, but treatment-related cardiac dysfunction may compromise treatment continuity and long-term cardiovascular health. This systematic review and meta-analysis evaluat...